Hong Kong Stocks Close Up 0.8% on Aug 20 as mRNA Vaccine Breakthrough Ignites Biotech Sector
Nashnova编辑部
The Hang Seng Index rose 0.8% to 25,698 on August 20 as a landmark mRNA cancer-vaccine trial sparked a biotech rally, but Industrial Securities warned the broader advance remains a valuation repair — not an earnings-driven reversal.
What moved and by how much?
The Hang Seng closed up 0.8% (+203 pts) at 25,698; turnover hit HK$269.1 billion. The Hang Seng China Enterprises Index gained 0.9%; the Hang Seng Tech Index rose 0.39%.
The index was up as much as 1.1% at midday before trimming gains into the close. This means → some money took profits late in the session; sentiment was not one-directionally euphoric.
Industrial Securities' read: the rally is driven by low-valuation repair, fund rebalancing, and an extreme-sentiment reversal — not yet a broad earnings-upgrade cycle.
How far has the valuation repair run?
The HSI's forward P/E — how many times next year's earnings the market is willing to pay — has recovered from 9.7x in late June to 10.5x, back near its long-term average. In plain terms = the cheapest phase is over; further upside needs fresh catalysts.
The Hang Seng Tech P/E has climbed to 16.1x, still about 0.9 standard deviations below its historical mean. This means → the tech basket retains a wider margin of safety, but the discount also signals lingering skepticism about tech earnings.
What exactly did the mRNA cancer-vaccine trial show?
Moderna and Merck announced that their co-developed personalized mRNA cancer vaccine cleared its first Phase III trial: in high-risk melanoma patients, combination with a PD-1 inhibitor — a drug that helps the immune system recognize cancer cells — cut recurrence risk by nearly 50%, with efficacy lasting at least 5 years.
Huachuang Securities highlighted the core breakthrough: mRNA's rapid, flexible, multi-antigen encoding enables a true "one patient, one drug" personalized cancer vaccine. In plain terms = mRNA had only proven itself against infectious diseases (e.g. COVID); this is the first time it passed the highest-level clinical bar in oncology.
If approved, this would be the first mRNA cancer therapy to reach the market. Analysts expect the earliest approval next year.
Which Hong Kong-listed stocks caught fire?
Sciwind Biosciences (01244) surged 56.88% — the company's pipeline includes the world's first subcutaneous PDL1, the first WT1 tumor vaccine, and a proprietary LNP delivery system — the "packaging technology" that carries mRNA drugs into human cells.
Summit Therapeutics (01952) jumped 41.43%; MediTech (07666) +27.99%; GenScript Biotech (01548) +13.62%; Insilico Medicine (03696) +12.13%; XtalPi (02228) +11.27%.
This reflects the market repricing the entire mRNA value chain — not just the vaccine itself, but delivery tech and AI-driven drug-discovery platforms all rallied in sympathy.
How did blue chips perform after earnings?
Sino Biopharmaceutical (01177) gained 12.53%. Daiwa noted adjusted H1 net profit rose 92.3% YoY to RMB 3.34 billion, well above expectations; product gross margin climbed from 84% to 88.6%, and AI tools have boosted the commercial team's promotion efficiency by 30%.
CSPC Pharmaceutical (01093) rose 9.61%; Desi-B (02526) surged 27.05% — H1 model-service revenue grew 101.1% YoY, now 87% of total revenue, up from 52%.
On the downside, SMIC (00981) fell 1.23%, dragging 5.78 pts from the HSI; China Resources Beer (00291) slipped 2.47%; CNOOC Chemical (03983) dropped 7.64% after H1 net profit fell 20.78% YoY.
Why were gold and auto stocks also rising?
Gold: The U.S. Treasury announced it would at least double the size of its liquidity-support buyback operations for 10-to-30-year bonds. The 30-year yield fell, the dollar weakened, and precious-metals stocks rallied. Zijin Gold International (02259) jumped 11.25%; Zijin Mining (02899) gained 5.33%, contributing 16.98 pts to the HSI.
Autos: Nine government departments issued new support for NEV sales in rural areas. January-to-July cumulative NEV penetration hit 51.2%, crossing 50% for the first time; July export penetration reached 60%, a new record. Li Auto rose 5.53%, NIO +4.49%, XPeng +4.09%.
This means → the day's gains were not a single-theme story — mRNA was the emotional trigger, but gold benefited from U.S. Treasury policy and autos from domestic policy plus export data, all three threads firing at once.
Content is for reference only, not financial advice.